A SENSITIVE AND ECONOMICAL DIFFERENT SPECTROSCOPIC METHODS DEVELOPMENT AND VALIDATION FOR THE QUANTIFICATION OF CAPECITABINE AND STRESS DEGRADATION STUDIES
DOI:
https://doi.org/10.22159/ijap.2023v15i3.47316Keywords:
Capecitabine, Spectroscopic methods, Method development, Validation, Stress degradation studiesAbstract
Objective: The present investigation aims to develop an efficient, rapid, sensitive, selective, linear, and accurate method for analyzing capecitabine in bulk and tablet dosage form by UV-spectroscopy approaches.
Methods: Capecitabine is an estimation by three different developed methods with different UV detection, method A (zero-order spectrophotometric method) at 239 nm, method B (first-order spectrophotometric method) at 231 nm, and method C (area under the curve spectrophotometric method) at 230 to 248 nm. The method's validation and stress degradation studies were done following the International Conference on Harmonization (ICH) guidelines.
Results: The methods were validated using the prescribed parameters like system suitability, LOD, LOQ, accuracy, precision, robustness, specificity, etc. The relative standard deviation (% RSD) of the peak area observed in each case was found within the accepted range (<2%). The linearity study's coefficient of correlation (R2) value was<0.99. The methods were quantified accurately in the presence of degraded products.
Conclusion: The developed simple and economical method is a suitable option for the qualitative and quantitative study of capecitabine in bulk and tablets, even in its degraded products, which may arise because of oxidation, hydrolysis, thermal, and photolytic decomposition.
Downloads
References
Pentheroudakis G, Twelves C. The rational development of capecitabine from the laboratory to the clinic. Anticancer Res. 2002 Nov-Dec;22(6B):3589-96. PMID 12552961.
Gelmon K, Chan A, Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist. 2006 Feb;11Suppl 1:42-51. doi: 10.1634/theoncologist.11-90001-42, PMID 16971739.
Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Anticancer Drugs. 2009 Apr;20(4):217-29. doi: 10.1097/CAD.0b013e3283293fd4, PMID 19247178.
O’Shaughnessy JA, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert NJ. Capecitabine monotherapy: a review of studies in first-line her-2-negative metastatic breast cancer. Oncologist. 2012 Apr;17(4):476-84. doi: 10.1634/theoncologist.2011-0281, PMID 22418569.
Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003 Feb;63(2):217-36. doi: 10.2165/00003495-200363020-00009, PMID 12515569.
Sternberg CN, Reichardt P, Holland M. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. Eur J Oncol Nurs. 2004;8Suppl 1:S4-S15. doi: 10.1016/j.ejon.2004.06.005, PMID 15341878.
Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005 Jan;27(1):23-44. doi: 10.1016/j.clinthera.2005.01.005, PMID 15763604.
Cadoo KA, Gajria D, Suh E, Patil S, Theodoulou M, Norton L. Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 d on and 7 d off): a systematic review. 2016 Mar;2:16006.
Kotsori AA, Noble JL, Ashley S, Johnston S, Smith IE. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first-line treatment? Breast. 2010 Oct;19(5):377-81. doi: 10.1016/j.breast.2010.03.023, PMID 20392643.
Rothenberg ML. Current status of capecitabine in the treatment of colorectal cancer. Oncol (Williston Park). 2002 Dec;16(12)Suppl 14:16-22. PMID 12520635.
McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs. 2001 Feb;61(15):2309-26. doi: 10.2165/00003495-200161150-00015, PMID 11772141.
Kurra P, Babu PS, Babu K. Development and validation of UV spectrophotometric method and RP-HPLC method for estimation of capecitabine in bulk and tablet dosage forms. Int J Appl Pharm. 2016 Jan;8(3):24-9.
Kumbhar SC, Salunkhe VR. UV spectrophotometric method development for capecitabine eudragit and chitosan-based microspheres and its validation. IJPBR. 2013 Mar;1(3):32-8. doi: 10.30750/ijpbr.1.3.7.
Bhatia MS, Raut JN, Barve AC, Patil PS, Jadhav SD. HPLC assay method development and validation for quantification of capecitabine in tablets and forced degradation samples. Marmara Pharm J. 2017 Mar;21(3):660-8. doi: 10.12991/marupj.323588.
Ramakrishna B, Mondal S, Chakraborty S. A new stability indicating method development and validation report for the assay of nivolumab by RP-UPLC. J Pharm Neg Results. 2022 Nov;13(7):1020-32.
Andhale SM, Nikalje APG. Simultaneous estimation of azilsartan and cilnidipine in bulk by RP-HPLC and assessment of its applicability in marketed tablet dosage form. Int J App Pharm. 2022 Jan;14(1):116-23. doi: 10.22159/ijap.2022v14i1.42208.
Ramakrishna B, Mondal S, Chakraborty S. Development and validation of novel method for the determination of favipiravir and peramivir using reverse-phase ultraperformance liquid chromatography. Ymer. 2022 Nov;21(10):1618-32.
Munir MA, Inayatullah A, Ibrahim S, Rimba Putri IR, Emelda E, Fatmawati A. A modest UV spectrophotometric assisted by chemometric approach for verification of acetaminophen level in various manufactured tablets and syrups in Indonesian pharmacies. Int J App Pharm. 2023 Jan;15(1):195-205. doi: 10.22159/ijap.2023v15i1.46290.
Vainchtein LD, Rosing H, Schellens JHM, Beijnen JH. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5′-deoxy-5-fluoro cytidine, 5′-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomed Chromatogr. 2010 Apr;24(4):374-86. doi: 10.1002/bmc.1302, PMID 19650151.
Licea Perez H, Wang S, Bowen C. Development of a sensitive and selective LC-MS/MS method for the determination of alpha-fluoro-beta-alanine, 5-fluorouracil and capecitabine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr;877(11-12):1040-46. doi: 10.1016/j.jchromb.2009.02.025, PMID 19285927.
Wang Z, Li X, Yang Y, Zhang F, Li M, Chen W. A sensitive and efficient method for determination of capecitabine and its five metabolites in human plasma based on one-step liquid-liquid extraction. J Anal Methods Chem. 2019 Jan;2019:9371790. doi: 10.1155/2019/9371790, PMID 30719375.
United States pharmacopoeia. The United States of America Pharmacopeial Convention. Vol. 3669. US Pharmacopeia 42; 2019; II. p. NF37.
Anonymous. Validation of analytical procedures: methodology. International Conference on Harmonization. Vol. Q2B (CPMP/ICH/281/95); 2005.
Mondal S, Reddy GS, Mondal P, Prathyusha VS, Nair AP, Rahaman ST. A new stability indicating ultra-performance liquid chromatography-PDA method for the estimation of valganciclovir in bulk and tablet dosage form. Pharm Methods. 2018 Dec;9(2):94-8. doi: 10.5530/phm.2018.2.16.
Seshukumar D, Abhishek GG, Kona SS, Gupta RS, Semwal VP. Development and validation of stability indicating RP-UPLC method for simultaneous determination in fixed-dose combination of Ezetimibe and Simvastatin. J Chromatogr Sep Tech. 2012 Mar;3(3):1-7.
Lasure A, Ansari A, Kalshetti M. UV Spectrophotometric analysis and validation of acyclovir in solid dosage form. Int J Curr Pharm Sci 2020;12:100-3. doi: 10.22159/ijcpr.2020v12i2.37501.
Published
How to Cite
Issue
Section
Copyright (c) 2023 KALLAM JEEVAN SAI, SUMANTA MONDAL, SUBHADIP CHAKRABORTY, BABY NALANDA REVU
This work is licensed under a Creative Commons Attribution 4.0 International License.
